Bioanalytical for RNA Therapeutics
Pyxant Labs offers leading bioanalytical capabilities for the assay of RNA therapeutics. Our platforms include LC/MS-MS and hybridization assays for both non-GLP and regulatory development studies for serum, plasma, and a wide range of tissues.
Our experience includes the development and regulatory validation of LC/MS-MS assays for oligonucleotide therapeutics in tissues. Pyxant Labs has successfully applied our LC/MS-MS platform (SCIEX 4000 and 5000 tandem mass spectrometers) for the study of these compounds in the most difficult tissue scenarios, including GLP liver and lung assays for regulatory development studies.
Pyxant Labs also offers same-day same-lab bioanalytical assay of RNA therapeutics samples by hybridization assay. Our method development and validation personnel for hybridization assays, coupled with similar capabilities on the LC/MS-MS platform, offer the leading combined capabilities within any bioanalytical CRO.
Our RNA therapeutics bioanalytical platforms include the following equipment, all validated for GLP studies.
- TECAN Infinite M200 UV/fluorescence 96-well plate reader, and related shakers and washers
- Precellys Model 24 tissue sample extractor
- Applied Biosystems API 5000 and API 4000 LC/MS-MS systems
- Waters AcQuity UPLC system
- TOMTEC Quadra 3 automated sample preparation system
- Symbiosis Pharma online extraction system
Pyxant Labs also is leading the advancement of state-of-the-art bioanalytical assay technologies for RNA therapeutics through our active development of LC-hybridization/MS-MS capabilities.